Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Arch Ophthalmol. 2012 Sep 1;130(9):1153–1161. doi: 10.1001/archophthalmol.2012.1107

Table 2. Change in Visual Acuity and Optical Coherence Tomography Central Subfield Thickness from Baseline to 1 Year by Participant Demographic and Medical Disease Characteristics.

Change in Visual Acuity Change in OCT CSF Thickness Visual Acuity Improvement of >10 letters and ≥20% reduction in OCT CSF Thickness

N Median (25th, 75th Quartile) Univariate/Multivariate P-values N Median (25th, 75thQuartile) Univariate/MultivariateP-values N % Univariate/MultivariateP-values
Total 338 +9 (+4, +15) 334 −116 (−209, −44) 334 37%

Race 0.87/-- 0.008/-- 0.08/--
Non-White 91 +9 (+5, +15) 88 −151 (−227, −78) 88 44%
White 247 +9 (+3, +15) 246 −104 (−192, −34) 246 35%
Gender 0.94/-- 0.81/-- 0.36/--
Women 145 +9 (+5, +15) 145 −119 (−210, −34) 145 39%
Men 193 +9 (+3, +15) 189 −115 (−207, −46) 189 36%
Age <0.001/<0.001 0.26/-- 0.002/0.003
<60 years 114 +11 (+5, +16) 114 −133 (−258, −63) 114 48%
≥60 years 224 +8 (+3, +14) 220 −109 (−192, −37) 220 32%
Diabetes Type 0.65/-- 0.03/-- 0.31/--
Type 1 23 +7 (+3, +12) 23 −95 (−127, −44) 23 26%
Type 2 309 +9 (+4, +15) 305 −122 (−212, −44) 305 38%
Diabetes Duration <0.001/-- 0.16/-- 0.04/--
<15 years 128 +10 (+5, +16) 128 −151 (−226, −57) 128 40%
≥15 years 210 +8 (+3, +15) 206 −103 (−181, −35) 206 36%
Mean Arterial Blood Pressure 0.03/-- 0.57/-- 0.19/--
≥100 mmHg 140 +11 (+5, +16) 138 −142 (−242, −47) 138 44%
<100 mmHg 198 +8 (+2, +15) 196 −109 (−179, −37) 196 33%
HbA1c 0.18/-- 0.94/-- 0.67/--
< 7.5 % 170 +8 (+3, +14) 167 −133 (−221, −49) 167 35%
≥ 7.5 % 161 +9 (+4, +16) 160 −101 (−195, −34) 160 39%
Hypertension 0.43/-- 0.96/-- 0.71/--
No 69 +9 (+4, +15) 68 −105 (−238, −43) 68 38%
Yes 269 +9 (+4, +15) 266 −120 (−203, −44) 266 37%
Elevated Cholesterol 0.94/-- 0.64/-- 0.83/--
No 117 +9 (+3, +16) 115 −130 (−241, −62) 115 40%
Yes 221 +9 (+4, +15) 219 −110 (−189, −35) 219 36%
Cardiovascular Disease 0.55/-- 0.57/-- 0.74/--
No 246 +9 (+3, +15) 243 −122 (−206, −44) 243 38%
Yes 92 +10 (+4, +15) 91 −99 (−212, −43) 91 35%
Renal Disease 0.87/-- 0.26/-- 0.71/--
No 314 +9 (+4, +15) −113 (−209, −42) 310 37%
Yes 24 +10 (+6, +15) 24 −136 (−215, −73) 24 46%
Neurologic Disease 0.21/-- 0.48/-- 0.87/--
No 266 +9 (+3, +15) 262 −113 (−210, −44) 262 37%
Yes 72 +11 (+6, +18) 72 −130 (−194, −44) 72 39%
Insulin Use 0.56/-- 0.30/-- 0.56/--
No 132 +9 (+5, +15) 131 −141 (−235, −62) 131 37%
Yes 206 +9 (+3, +15) 203 −100 (−189, −34) 203 38%
Prescribed Glitazones 0.71/-- 0.07/-- 0.57/--
No 269 +9 (+4, +15) 266 −110 (−192, −44) 266 36%
Yes 69 +8 (+4, +16) 68 −160 (−263, −45) 68 41%
Prescribed Statins 0.87/-- 0.88/-- 0.93/--
No 143 +9 (+4, +16) 141 −120 (−210, −62) 141 38%
Yes 195 +9 (+4, +15) 193 −112 (−206, −34) 193 37%

DME = diabetic macular edema; OCT = optical coherence tomography; CSF= central subfield thickness, HbA1c = hemoglobin A1c

‘Univariate’ P-values are adjusted for baseline level of the outcome (visual acuity, OCT CSF thickness, or both). Characteristics with P<0.10 were included in a multivariate model and those with P<0.01 were retained; P-values < 0.01 in the final multivariate models appear in bold.

Continuous version of variable used in model to obtain P-value, categories are shown for ease of interpretation only